NCT00398528View on ClinicalTrials.gov

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

TerminatedOBSERVATIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2006

Study Completion Date

November 30, 2007

Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
DRUG

Glatiramer acetate, (Copaxone®)

DRUG

IFN-β-1a, (Avonex®)

Trial Locations (5)

53215

Aurora St. Luke's Medical Center, Milwaukee

53226

Medical College of Wisconsin, Milwaukee

53792

University of Wisconsin - Madison, Madison

90033

University of Southern California, Los Angeles

98104

Minor & James Medical, Seattle

Sponsors

Lead Sponsor

Neurognostics
All Listed Sponsors
lead

Neurognostics

INDUSTRY

NCT00398528 - An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter